TROG Cancer Research has been improving the way in which radiotherapy is delivered to cancer patients for almost 30 years. The research our Australian and New Zealand-based members conduct is renowned internationally.
We were the recipient of the 'Innovation in Cancer Clinical Trials' award at the NSW Premier's Awards for Outstanding Cancer Research in 2013.
All types of cancers / one treatment focus
TROG's research focus is on one type of treatment, radiotherapy, for the many types of cancers it can treat such as breast, lung, prostate, skin, head and neck.
Like chemotherapy and surgery, radiotherapy is a widely used cancer treatment. In fact, around 1 in 6 people will receive radiotherapy in their lifetime. Radiotherapy controls and even cures various cancers using high energy x-rays and similar rays, and cutting-edge research is continually improving techniques.
We are one of the largest clinical cancer trial groups in Australia and New Zealand, specialising in radiotherapy clinical trials.
TROG Cancer Research is one of the largest clinical trials groups in Australia and works with its members, hospitals, universities and trial coordinating centres to sustain vital cancer research for our community.
Working with more than 70 cancer treatment centres in the Trans-Tasman, TROG has launched more than 100 trials with the help of 14,500 patients.
TROG is one of 14 clinical trials groups who are members of the National Cancer Cooperative Trials Group, a federal government initiative which supports Australia's capacity to develop industry-independent cancer clinical trials.
We are a registered charity
TROG Cancer Research (or Trans Tasman Radiation Oncology Group - TROG) is registered charity in Australia, holding Deductible Gift Recipient (DGR) status, which means that donations over $2 are tax deductible
The Trans Tasman Radiation Oncology Group (TROG) formed in 1989 when members of seven radiotherapy centres across Australia and New Zealand formed a clinical trials group to advance the study of cancers that could be treated with radiotherapy. The aim was to contribute to a process of continual improvement in cancer treatment for the benefit of patients in the Trans-Tasman region and internationally.